iRhythm Data Presented at the American Heart Association 2024 Scientific Sessions Reinforce Clinical and Health Economic Value of Zio Long-Term Continuous Monitoring

Core Insights - iRhythm Technologies presented five new studies at the American Heart Association's 2024 Scientific Sessions, emphasizing its commitment to enhancing ambulatory cardiac monitoring services to improve patient outcomes and healthcare resource utilization [1][2][6] Group 1: Long-Term Continuous Monitoring (LTCM) - The studies focus on three areas: patient engagement through digital tools, evaluating arrhythmia patterns during sleep and activity, and assessing the economic impact of early arrhythmia detection in patients with type 2 diabetes and chronic obstructive pulmonary disease (COPD) [2][3] - Two studies validated the effectiveness of digital health tools in improving patient compliance with device return and highlighted the importance of patient feedback in enhancing the Zio® monitor [3][4] Group 2: Patient Engagement and Satisfaction - A study showed that using a smartphone app and text messaging significantly increased compliance rates in patients undergoing long-term continuous ambulatory cardiac monitoring, with compliance at 94.8% when both tools were used compared to 74.6% without [8] - Another study involving over 300,000 patients demonstrated that the new Zio® monitor had a 14-percentage point improvement in wear comfort compared to the previous generation device [9] Group 3: Arrhythmia Patterns - Two studies assessed the feasibility of using the Zio system to monitor arrhythmias in relation to sleep and activity, providing insights for personalized arrhythmia management [4][10] - The largest study analyzed 23,962 patients and identified distinct arrhythmia patterns associated with sleep and activity, revealing that certain arrhythmias were more likely to occur during specific states [11][12] Group 4: Economic Impact of Early Detection - A retrospective analysis indicated that early detection of arrhythmias in patients with type 2 diabetes and COPD could significantly reduce healthcare resource utilization and associated costs, with annual costs per patient being substantially higher for those with arrhythmias [13] - The study found that arrhythmia patients had more than double the hospitalization rates compared to non-arrhythmia patients, highlighting the economic burden of untreated arrhythmias [13] Group 5: iRhythm's Commitment to Evidence - iRhythm's clinical evidence program includes over 100 original research publications and insights from more than 1.5 billion hours of curated heartbeat data, reflecting its dedication to improving patient outcomes through rigorous scientific evidence [6][14]